Tetrahedron 68 (2012) 6298-6304

Contents lists available at SciVerse ScienceDirect

Tetrahedron



journal homepage: www.elsevier.com/locate/tet

Synthesis of arylated xanthones by site-selective Suzuki–Miyaura reactions of the bis(triflate) of 1,3-dihydroxyxanthone

Omer A. Akrawi^a, Hamid H. Mohammed^{a,b}, Tamás Patonay^c, Alexander Villinger^a, Peter Langer^{a,d,*}

^a Institut für Chemie, Universität Rostock, Albert Einstein Str. 3a, 18059 Rostock, Germany

^b Department of Chemistry, College of Sciences, University of Al-Mustansiriyah, Baghdad, Iraq

^c Department of Chemistry, University of Debrecen, H-4032 Debrecen, Egyetem tér 1, Hungary

^d Leibniz-Institut für Katalyse an der Universität Rostock e.V., Albert Einstein Str. 29a, 18059 Rostock, Germany

ARTICLE INFO

Article history: Received 20 March 2012 Received in revised form 2 May 2012 Accepted 11 May 2012 Available online 18 May 2012

Keywords: Palladium Suzuki–Miyaura reaction Cross-coupling O-Heterocycles Xanthones Regioselectivity

ABSTRACT

Arylated xanthones were prepared by site-selective Suzuki–Miyaura reactions of the bis(triflate) of 1,3dihydroxyxanthone. The first attack occurs at the sterically less encumbered position 3. The siteselectivity is in contrast to the bis(triflate) of 1,3-dihydroxyanthraquinone.

© 2012 Elsevier Ltd. All rights reserved.

1. Introduction

Xanthones are an important family of oxygenated heterocyclic compounds that occur in a variety of higher plant families, such as Gentianaceae,¹ Guttiferae,² and in a few families of fungi and lichens (Fig. 1).³ Some xanthone-containing plants, for example, Cratoxylum cochinchinense (Lour.), have been used as traditional medicines to treat fever, coughing, diarrhea, itching, ulcers, and abdominal complaints.⁴ Lesch and Braese described the xanthone moiety as a so-called 'privileged structure', since members of this structural class are able to interact with different types of drug targets.⁵ The great interest in synthetic and naturally occurring xanthones is due to their pharmacological properties. They have been reported to act as antioxidant,⁶ antiallergic,⁷ antibacte-rial,⁸ antifungal,⁹ anti-inflammatory,¹⁰ antimalarial,¹¹ HIV-1 in-hibitory,¹² antidepressant,¹³ antidiabetic,¹⁴ and antitumor agents. For example, paeciloxanthone has been reported to exhibit antitumor activity and AChE inhibition.³ 5,6-Dimethylxanthone-4-acetic acid (DMXAA) is a synthetic small molecule that shows activity as a vascular disrupting agent.¹⁵







Fig. 1. Xanthone synthetic and natural products.

There are various known synthetic approaches to the xanthone framework. The classic ones involve the assembly of two benzene rings through a pyran unit.¹⁶ The most commonly reported are the Friedel-Crafts acylation, Fries rearrangement and Ullmann condensation.¹⁶ The direct formation of the xanthone moiety by reaction of arynes with substituted benzoates¹⁷ or by Diels-Alder reaction¹⁸ has also been reported. While the (known) biogenetic formation of xanthones largely dictates the nature and position of substituents.¹⁹ the development of new synthetic approaches allows to prepare other types of substituted xanthones for biological screening. The presence of aryl groups located at the xanthone core has only been reported for a few synthetic derivatives. Arylated xanthones have been prepared by reaction of 3-(1-alkynyl)chromones with 1,3-dicarbonyl compounds²⁰ or acetonitriles²¹ or by condensation of 2-methylchromone with cinnamaldehydes.²² Arylated xanthones have also been synthesized by using transition metal catalyzed reactions, such as the domino Heck reaction of 3-bromo-2-styryl-chromones and styrenes^{23–25} or by Suzuki crosscoupling reactions of brominated xanthones.²⁶ Herein, we report the synthesis of arylated xanthones by Suzuki-Miyaura reactions of the bis(triflate) of 1,3-dihydroxyxanthone. The reactions proceed with excellent site-selectivity in favor of position 3.

The reaction of 1,3-(dihydroxy)xanthone with triflic anhydride afforded the bis(triflate) **2** in 80% yield (Scheme 1).



Scheme 1. Synthesis of **2.** Conditions: i, **1** (1.0 equiv), Tf_2O (2.4 equiv), pyridine (4.0 equiv), CH_2CI_2 , 20 °C, 12 h.

The reaction of bis(triflate) **2** with arylboronic acids **3a–g** (2.4 equiv) afforded the 1,3-diarylxanthones **4a–g** in 70–95% yield (Scheme 2, Table 1). The best yields were obtained when the reaction was carried out using Pd(PPh₃)₂Cl₂ (10 mol %) as the catalyst, KF (6.6 equiv) as the base, and toluene as the solvent (Table 2). Both electron rich and electron poor arylboronic acids could be successfully employed.



Scheme 2. Synthesis of 4a-g. Conditions: i, 2 (1.0 equiv), ArB(OH)₂ (2.4 equiv), Pd(PPh₃)₂Cl₂ (10 mol %), KF (6.6 equiv), toluene, 120 °C, 5 h.

Table 1		
Synthesis	of 1,3-diarylxanthones	4a-g

Table 1

3,4	Ar	% (4) ^a
a	$4-(MeO)C_6H_4$	95
b	2-(MeO)C ₆ H ₄	75
с	4-EtC ₆ H ₄	90
d	3,5-Me ₂ C ₆ H ₃	70
e	3-ClC ₆ H ₄	85
f	4-ClC ₆ H ₄	81
g	$4-FC_6H_4$	73

^a Yields of isolated compounds.

Table 2

Optimization of the synthesis of **4a**,**g** (all reactions were carried out at 120 °C for 5 h)

Entry	Base ^a	Solvent ^b	Catalyts ^c	% (4a) ^d	% (4g) ^d
1	K ₃ PO ₄	Dioxane	$[Pd(PPh_3)_4]$	42	25
2	K ₃ PO ₄	Toluene	[Pd(PPh ₃) ₄]	51	38
3	KF	Dioxane	$[Pd(PPh_3)_4]$	57	42
4	KF	Toluene	$[Pd(PPh_3)_4]$	65	47
5	K ₃ PO ₄	Dioxane	$[Pd(PPh_3)_2 Cl_2]$	49	33
6	K ₃ PO ₄	Toluene	$[Pd(PPh_3)_2 Cl_2]$	60	40
7	KF	Dioxane	$[Pd(PPh_3)_2 Cl_2]$	74	58
8	KF	Toluene	$[Pd(PPh_3)_2 Cl_2]$	95	73

^a K₃PO₄ (3.0 equiv) or KF (6.6 equiv) per 0.15 mmol of **2**.

^b 2 ml per 0.15 mmol of **2**.

^c 10 mol % per 0.15 mmol of **2**.

^d Yield of isolated products.

The reaction of bis(triflate) **2** with arylboronic acids **3a,b,d–j** (1.1 equiv) afforded the 3-aryl-1-(trifluoromethylsulfonyloxy)xanthones **5a–i** in 72–91% yield (Scheme 3, Table 3). The best yields were obtained when the reaction was carried out using Pd(PPh₃)₄ (3 mol %) as the catalyst, K₃PO₄ (1.5 equiv) as the base, and dioxane as the solvent. Both electron rich and electron poor as well as functionalized arylboronic acids could be successfully employed. While the synthesis of **4a–g** was carried out at 120 °C, the synthesis of **5a–i** had to be carried out at 80 °C to achieve a good site-selectivity. Mixtures of mono- and diarylated products were obtained when the reaction was carried out at 120 °C. The structure of **5i** was independently confirmed by X-ray crystal structure analysis (Fig. 2).²⁷



Scheme 3. Synthesis of **5a**–i. Conditions: i, **2** (1.0 equiv), ArB(OH)₂ (1.1 equiv), Pd(PPh₃)₄ (3 mol %), K₃PO₄ (1.5 equiv), dioxane, 80 °C, 7 h.

Table 3			
Synthesis	of	5a	ı—i

3	5	Ar	% (5) ^a
a	a	4-(MeO)C ₆ H ₄	90
b	b	2-(MeO)C ₆ H ₄	77
с	с	3,5-Me ₂ C ₆ H ₃	72
d	d	3-ClC ₆ H ₄	80
e	е	4-ClC ₆ H ₄	85
f	f	$4-FC_6H_4$	76
g	g	$4-tBuC_6H_4$	91
h	h	4-(MeCO)C ₆ H ₄	83
i	i	$4-CF_3C_6H_4$	86

^a Yields of isolated compounds.

The one-pot reaction of bis(triflate) **2** with two different arylboronic acids (sequential addition) afforded the 1,3-diarylxanthones **6a–e** in 63–85% yield (Scheme 4, Table 4). The best yields were obtained when the reaction was carried out using, for the first step, Pd(PPh₃)₂Cl₂ (3 mol %), KF (3.3 equiv), and toluene (85 °C, 16 h) and, for the second step, an additional amount of Pd(PPh₃)₂Cl₂ (6 mol %) (120 °C, 7 h). Both in the first and second step of the one-pot reaction, electron poor and rich arylboronic acids could be successfully used.



Fig. 2. Molecular structure of compound 5i.



 $\begin{array}{l} \mbox{Scheme 4. Synthesis of 6a-e. Conditions: i, 2 (1.0 equiv), $Ar^1B(OH)_2$ (1.0 equiv), $Pd(PPh_3)_2Cl_2$ (3 mol %), KF (3.3 equiv), toluene, 85 °C, 16 h. ii, $Ar^2B(OH)_2$ (1.4 equiv), $Pd(PPh_3)_2Cl_2$ (6 mol %), 120 °C, 7 h. } \end{array}$

Table 4 Synthesis of 6a–e

3	6	Ar ¹	Ar ²	% (6) ^a
c,f	a	4-EtC ₆ H ₄	4-ClC ₆ H ₄	70
h,a	b	4-tBuC ₆ H ₄	4-(MeO)C ₆ H ₄	78
g,b	с	$4-FC_6H_4$	2-(MeO)C ₆ H ₄	81
g,k	d	$4-FC_6H_4$	2-MeC ₆ H ₄	63
j,a	e	$4-CF_3C_6H_4$	4-(MeO)C ₆ H ₄	85

^a Yields of isolated compounds.

We have earlier reported that the one-pot reaction of the bis(triflate)**7** of 1,3-dihydroxyanthraquinone with two different arylboronic acids afforded 1,3-diaryl-anthraquinones, such as derivative **8** (Scheme 5). The first attack occurred at position $1.^{28}$



Scheme 5. Synthesis of **8a,b**. Conditions: i, **4** (1.0 equiv), $Ar^{1}B(OH)_{2}$ (1.0 equiv), $Pd(PPh_{3})_{4}$ (3 mol %), $K_{3}PO_{4}$ (3.0 equiv), dioxane, 60 °C, 30 h; ii, $Ar^{2}B(OH)_{2}$ (1.2 equiv), $Pd(PPh_{3})_{4}$ (3 mol %), 100 °C, 5 h.

Palladium catalyzed cross-coupling reactions usually proceed by site-selective attack to the more electron deficient or less sterically hindered position.²⁹ In case of bis(triflate) **2**, the site-selectivity in favor of position 3 can be explained by the fact that position 3 is less

sterically hindered than position 1 (Scheme 6). On the other hand, position 1 is more electron deficient. As mentioned above, we have earlier observed that Suzuki–Miyaura reactions of bis(triflate) 7 of 1,3-dihydroxyanthraquinone proceed with very good siteselectivity in favor of position 1 (Scheme 5).²⁸ The ¹H NMR chemical shifts of the parent compounds, in which the OTf or Br group is replaced by a hydrogen atom, have been reported to represent a good tool to predict the electronic character of the atoms and to predict the regioselectivity of palladium(0) catalyzed cross-coupling reactions.³⁰ The ¹H NMR chemical shifts (in CDCl₃) of anthraquinone are 8.34 ppm (1-H) and 7.80 ppm (3-H), while the values for xanthone are 8.32 ppm (1-H) and 7.70 ppm (3-H). The chemical shifts of the protons 1-H and 3-H of both respective compounds are very similar. Therefore, the change of the regioselectivity is surprising. It might be explained by the electron donating effect of the oxygen atom of the xanthone ring.



Scheme 6. Possible explanation for the site-selectivity of the Suzuki reactions of 2.

2. Experimental section

2.1. Synthesis of 9-oxo-9*H*-xanthene-1,3-diyl bis(trifluoromethanesulfonate) (2)

To a CH₂Cl₂ (50 ml) solution of 1,3-dihydroxy-9H-xanthen-9one 1 (1.0 g, 4.4 mmol) pyridine (1.42 ml, 17.6 mmol) and Tf₂O (1.8 ml, 10.6 mmol) were added and reaction mixture was stirred at 20 °C under argon atmosphere for 12 h. In the reaction mixture toluene (20 ml) was added and concentrated in vacuo. Residue was chromatographed (EtOAc/heptanes) without aqueous work up to yield **2** as a white solid (1.73 g, 80%), mp: 156 °C. ¹H NMR (300 MHz, CDCl₃): δ=7.05 (d, 1H, J=2.3 Hz, ArH), 7.37−7.45 (m, 2H, ArH), 7.49 (d, 1H, J=2.4 Hz, ArH), 7.73 (ddd, 1H, J=1.7, 7.1, 8.6 Hz, ArH), 8.28 (dd, 1H, J=1.6, 8.1 Hz, ArH). ¹⁹F NMR (282.4 MHz, CDCl₃): $\delta = -73.1$, -72.2. ¹³C NMR (62.9 MHz, CDCl₃): δ=111.9, 112.1 (CH), 115.5 (C), 117.6 (CH), 118.6 (q, J_{CF}=320.9 Hz, CF₃), 118.8 (q, J_{CF}=320.6 Hz, CF₃), 121.8 (C), 125.5, 127.1, 136.1 (CH), 148.6, 151.5, 155.1, 157.5 (C), 173.9 (CO). IR (KBr): v=3104 (w), 1663 (m), 1611 (s), 1592, 1570, 1471, 1460 (m), 1423 (s), 1353, 1334 (w), 1312 (m), 1280 (w), 1273, 1237 (m), 1202 (s), 1165, 1150 (m), 1135, 1109 (s), 1044, 1020 (m), 991 (s), 922 (w), 884 (s), 855 (w), 842, 810, 799, 768, 758 (m), 722 (w), 712 (m), 697, 684, 682 (w), 614, 592, 585, 570 (m), 545 (w) cm⁻¹. GC–MS (EI, 70 eV): m/z (%)=492 ([M]⁺, 80), 428 (30), 364 (7), 336 (13), 267 (100). HRMS (EI, 70 eV): calcd for C₁₅H₆F₆O₈S₂ [M]⁺: 491.94028; found: 491.94039.

2.2. General procedure A for Suzuki–Miyaura cross-coupling reactions to synthesize 4a–g

A toluene solution of 9-oxo-9*H*-xanthene-1,3-diyl bis(tri-fluoromethanesulfonate) **2** (0.15 mmol), Pd(PPh₃)₂Cl₂ (10 mol %), arylboronic acid (2.4 equiv), and KF (6.6 equiv) was heated at 120 °C for 5 h under argon atmosphere. After cooling to 20 °C, H₂O was added and the reaction mixture was extracted with CH₂Cl₂ (3×25 ml) organic layers were dried (Na₂SO₄), filtered and concentrated in vacuo. The residue was purified by column chromatography (EtOAc/heptanes).

2.2.1. 1,3-Bis(4-methoxyphenyl)-9H-xanthen-9-one (4a). Starting with 2 (74 mg, 0.15 mmol), Pd(PPh₃)₂Cl₂ (10 mg, 10 mol %), 4methoxyphenylboronic acid (55 mg, 0.36 mmol), KF (58 mg, 1 mmol), and toluene (2 ml), compound **4a** was isolated as a yellow solid (58 mg, 95%), mp: 196-198 °C. Reaction temperature: 120 °C for 5 h. ¹H NMR (300 MHz, CDCl₃): δ =3.78, 3.80 (s, 6H, 2OCH₃), 6.90-6.95 (m, 4H, ArH), 7.22-7.27 (m, 3H, ArH), 7.29 (d, 1H, J=1.9 Hz, ArH), 7.39 (br d, 1H, J=8.3 Hz, ArH), 7.56-7.59 (m, 4H, ArH), 8.12 (dd, 1H, J=1.6, 7.9 Hz, ArH). ¹³C NMR (62.9 MHz, CDCl₃): δ =54.2, 54.4 (OCH₃), 112.1, 113.3, 113.5, 116.3 (CH), 116.6, 121.9 (C), 122.7, 124.9, 125.9, 127.5, 128.8 (CH), 130.1, 133.2 (C), 133.3 (CH), 143.4, 144.7, 154.5, 156.8, 157.9, 159.4 (C), 175.7 (CO). IR (KBr): v=3060, 3044, 2995, 2962, 2917, 2838 (w), 1665, 1598 (s), 1553 (w), 1514 (s), 1474 (w), 1460, 1447 (s), 1430, 1388, 1355 (m), 1325 (w), 1309, 1283 (m), 1244, 1235 (s), 1189, 1176, 1169, 1148, 1109, 1099 (w), 1020 (s), 962, 944, 931, 924, 878, 851 (w), 820, 813, 793, 733 (s), 716, 698, 638, 621, 610, 602, 591, 581, 554 (w) cm^{-1} , GC-MS (EI, 70 eV): m/z (%)=408 ([M]⁺, 39), 407 ([M-H]⁺, 100), 365 (08), 321 (10), 263 (05). HRMS (EI, 70 eV): calcd for C₂₇H₁₉O₄ [M-H]⁺: 407.12779; found: 407.12780.

2.2.2. 1,3-Bis(2-methoxyphenyl)-9H-xanthen-9-one (4b). Starting with 2 (74 mg, 0.15 mmol), Pd(PPh₃)₂Cl₂ (10 mg, 10 mol %), 2methoxyphenylboronic acid (55 mg, 0.36 mmol), KF (58 mg, 1 mmol), and toluene (2 ml), 4b was isolated as a yellow solid (46 mg, 75%), mp: 158–160 °C. Reaction temperature: 120 °C for 5 h. ¹H NMR (300 MHz, CDCl₃): δ=3.62, 3.78 (s, 6H, 2OCH₃), 6.89−6.99 (m, 4H, ArH), 7.16-7.20 (m, 2H, ArH), 7.27-7.32 (m, 3H, ArH), 7.37 (d, 2H, J=7.9 Hz, ArH), 7.54–7.60 (m, 1H, ArH), 7.66 (d, 1H, J=1.6 Hz, ArH), 8.10 (dd, 1H, *J*=1.4, 7.9 Hz, ArH). ¹³C NMR (62.9 MHz, CDCl₃): δ=55.6, 55.7 (OCH₃), 110.3, 111.4, 117.4, 118.3 (CH), 118.8 (C), 120.4, 121.0 (CH), 122.0 (C), 123.5, 126.8, 128.5, 128.7, 129.4, 129.9, 130.9 (CH), 131.5 (C), 134.1 (CH), 139.6, 144.1, 155.6 (C), 156.6 (2C), 157.1 (C), 175.7 (CO). IR (KBr): v=3058, 3023, 2997, 2936, 2917, 2836 (w), 1659 (s), 1618 (m), 1605, 1595 (s), 1580, 1554 (w), 1495, 1467, 1461 (s), 1433, 1396, 1356 (m), 1312, 1295, 1270 (w), 1241, 1230 (s), 1181, 1170, 1160, 1147, 1132, 1117, 1097, 1065 (w), 1045 (m), 1020 (s), 947, 931 (m), 885 (w), 870, 840 (m), 810, 791, 772 (w), 752 (s), 728 (m), 697 (w), 674 (m), 647, 622, 599, 572, 553 (w) cm⁻¹. GC–MS (EI, 70 eV): *m/z* (%)=408 ([M]⁺, 01), 378 (26), 377 (100), 362 (11), 361 (41). HRMS (EI, 70 eV): calcd for C₂₇H₂₀O₄ [M]⁺: 408.13561; found: 408.13574.

2.2.3. 1,3-Bis(4-ethylphenyl)-9H-xanthen-9-one (**4c**). Starting with **2** (74 mg, 0.15 mmol), Pd(PPh₃)₂Cl₂ (10 mg, 10 mol %), 4ethylphenylboronic acid (54 mg, 0.36 mmol), KF (58 mg, 1 mmol), and toluene (2 ml), **4c** was isolated as a white solid (55 mg, 90%), mp: 123 °C. Reaction temperature: 120 °C for 5 h. ¹H NMR (300 MHz, CDCl₃): δ =1.18–128 (m, 6H, 2CH₃), 2.58–2.73 (m, 4H, 2CH₂), 7.20–7.25 (m, 7H, ArH), 7.35 (d, 1H, *J*=1.8 Hz, ArH), 7.40 (br d, 1H, *J*=8.1 Hz, ArH), 7.57 (d, 2H, *J*=8.3 Hz, ArH), 7.60–7.64 (m, 2H, ArH), 8.13 (dd, 1H, *J*=1.4, 7.9 Hz, ArH). ¹³C NMR (75.5 MHz, CDCl₃): δ =15.3, 15.5 (CH₃), 28.6, 28.7 (CH₂), 115.0, 117.4 (CH), 117.9, 122.9 (C), 123.8, 126.2, 127.0, 127.2, 127.3, 128.5, 128.6, 134.4 (CH), 136.2, 139.3, 143.0, 144.7, 145.7, 146.1, 155.6, 157.8 (C), 176.8 (CO). IR (KBr): v=3055, 3026, 2960, 2867, 2850 (w), 1658 (s), 1614 (w), 1598 (s), 1594 (w), 1574, 1519 (m), 1504 (w), 1467 (s), 1427 (m), 1408 (w), 1386, 1355 (m), 1335 (w), 1308 (s), 1261, 1199, 1186, 1170, 1144, 1121, 1108, 1100, 1060, 1019, 946 (w), 945, 928 (m), 897, 879, 862, 853 (w), 818, 756 (s), 727, 699, 670, 624, 606, 591, 582, 553, 532 (w) cm⁻¹. GC-MS (EI, 70 eV): m/z (%)=404 ([M]⁺, 47), 403 ([M-H]⁺, 100), 388 (12), 373 (08). HRMS (EI, 70 eV): calcd for C₂₉H₂₃O₂ [M-H]⁺: 403,16926; found: 403,16953.

2.2.4. 1,3-Bis(3,5-dimethylphenyl)-9H-xanthen-9-one (4d). Starting with 2 (74 mg, 0.15 mmol), Pd(PPh₃)₂Cl₂ (10 mg, 10 mol %), 3,5dimethylphenylboronic acid (54 mg, 0.36 mmol), KF (58 mg, 1 mmol), and toluene (2 ml), 4d was isolated as a white solid (42 mg, 70%), mp: 173–175 °C. Reaction temperature: 120 °C for 5 h. ¹H NMR (300 MHz, CDCl₃): δ =2.31 (br s, 12H, 4CH₃), 6.92 (br s, 2H, ArH), 6.99 (br s, 2H, ArH), 7.20-7.25 (m, 3H, ArH), 7.31 (d, 1H, J=1.8 Hz, ArH), 7.39 (dd, 1H, J=0.7, 8.4 Hz, ArH), 7.57-7.63 (m, 2H, ArH), 8.12 (dd, 1H, J=1.6, 8.0 Hz, ArH). ¹³C NMR (62.9 MHz, CDCl₃): δ=21.4, 21.5 (2CH₃), 115.1, 117.4 (CH), 118.0, 122.9 (C), 123.7, 125.3, 126.2, 126.3, 127.0, 128.9, 130.4, 134.3 (CH), 136.9, 138.6, 138.8, 142.0, 144.8, 146.3, 155.5, 157.5 (C), 176.6 (CO). IR (KBr): v=3030, 2996, 2914, 2852, 2727 (w), 1665 (s), 1615 (w), 1597, 1555 (s), 1512 (w), 1475 (m), 1462 (s), 1387, 1379, 1359, 1309 (m), 1290, 1265 (w), 1224 (m), 1167, 1151, 1141, 1131, 1106, 1082, 1034, 1018, 966, 946 (w), 841 (s), 808 (w), 792 (m), 758 (s), 731, 709, 702, 684 (w), 674, 656, 643 (m), 625, 608, 589, 554, 545 (w) cm⁻¹. GC–MS (EI, 70 eV): m/z (%)= 404 ([M]⁺, 53), 403 ([M–H]⁺, 100), 389 (22). HRMS (EI, 70 eV): calcd for C₂₉H₂₃O₂ [M–H]⁺: 403.16926; found: 403.16942.

2.2.5. 1,3-Bis(3-chlorophenyl)-9H-xanthen-9-one (4e). Starting with 2 (74 mg, 0.15 mmol), Pd(PPh₃)₂Cl₂ (10 mg, 10 mol %), 3chlorophenylboronic acid (56 mg, 0.36 mmol), KF (58 mg, 1 mmol), and toluene (2 ml), 4e was isolated as a white solid (53 mg, 85%), mp: 146-148 °C. Reaction temperature: 120 °C for 5 h. ¹H NMR (300 MHz, CDCl₃): δ =7.17–7.20 (m, 1H, ArH), 7.24–7.36 (m, 7H, ArH), 7.38-7.43 (m, 1H, ArH), 7.49-7.52 (m, 1H, ArH), 7.61–7.66 (m, 3H, ArH), 8.11 (dd, 1H, J=1.3, 8.0 Hz, ArH). ¹³C NMR (75.5 MHz, CDCl₃): δ=116.1, 117.5 (CH), 118.3, 122.7 (C), 124.1, 125.6, 125.9 (CH), 126.9 (2 CH), 127.4, 127.5, 128.5, 128.8, 129.0, 130.4 (CH), 133.6 (C), 134.8 (CH), 135.2, 140.4, 143.3, 143.4, 144.8, 155.5, 157.6, 176.4 (CO). IR (KBr): v=3054, 2954, 2920, 2850 (w), 1655 (s), 1616 (m), 1601, 1592, 1554 (s), 1515, 1494 (w), 1461 (s), 1414 (w), 1397, 1354 (m), 1338, 1303, 1289 (w), 1227 (m), 1189, 1176, 1169, 1137, 1131, 1081, 1074, 1057, 947 (w), 933 (m), 894, 872 (w), 857 (s), 830, 806 (w), 779, 752 (s), 728, 676, 668 (m), 650, 624, 585 (w) cm⁻¹. GC-MS (EI, 70 eV): m/z (%)=419 ([M-H, ³⁷Cl, ³⁷Cl]⁺, 25), 417 $([M-H, {}^{35}Cl, {}^{37}Cl]^+, 59), 415 ([M-H, {}^{35}Cl, {}^{35}Cl]^+, 100), 381 (05).$ HRMS (EI, 70 eV): calcd for C₂₅H₁₃Cl₂O₂ [M–H, ³⁵Cl, ³⁵Cl]⁺: 415.02871; found: 415.02871; calcd for C₂₅H₁₃Cl₂O₂ [M–H, ³⁵Cl, ³⁷Cll⁺: 417.02576: found: 417.02706.

2.2.6. 1,3-*Bis*(4-chlorophenyl)-9*H*-xanthen-9-one (**4f**). Starting with **2** (74 mg, 0.15 mmol), Pd(PPh₃)₂Cl₂ (10 mg, 10 mol %), 4-chlorophenylboronic acid (56 mg, 0.36 mmol), KF (58 mg, 1 mmol), and toluene (2 ml), **4f** was isolated as a white solid (51 mg, 81%), mp: 206–208 °C. Reaction temperature: 120 °C for 5 h. ¹H NMR (300 MHz, CDCl₃): δ =7.21–7.27 (m, 4H, ArH), 7.32–7.40 (m, 5H, ArH), 7.55 (d, 2H, *J*=8.5 Hz, ArH), 7.60–7.65 (m, 2H, ArH), 8.10 (dd, 1H, *J*=1.4, 7.9 Hz, ArH). ¹³C NMR (75.5 MHz, CDCl₃): δ =115.7, 117.5 (CH), 118.1, 122.7 (C), 124.1, 125.8, 126.9, 127.9, 128.6, 129.4, 129.9 (CH), 133.4 (C), 134.7 (CH), 135.3, 137.0, 140.1, 143.6, 145.0, 155.5, 157.7 (C), 176.6 (CO). IR (KBr): *v*=3103, 3087, 3069, 3053, 3034, 2952, 2918, 2850 (w), 1661 (s), 1618 (w), 1601 (s), 1547 (w), 1496, 1466 (m), 1420 (w), 1378, 1356 (m), 1340 (s), 1312, 1303 (w), 1296 (m), 1292, 1269 (w), 1108 (m), 964, 956 (w), 945 (m), 929, 907, 892, 872, 855 (w), 821, 809 (s), 759 (w), 750, 732 (m), 719, 704, 641,

618, 600 (w), 559, 547 (m) cm⁻¹. GC–MS (EI, 70 eV): m/z (%)=419 ([M–H, 37 Cl, 37 Cl]⁺, 18), 417 ([M–H, 35 Cl, 37 Cl]⁺, 73), 415 ([M–H, 35 Cl, 35 Cl]⁺, 100), 379 (06). HRMS (EI, 70 eV): calcd for C₂₅H₁₃Cl₂O₂ [M–H, 35 Cl, 35 Cl]⁺: 415.02871; found: 415.02852; calcd for C₂₅H₁₃Cl₂O₂ [M–H, 35 Cl, 37 Cl]: 417.02576; found: 417.02613.

2.2.7. 1.3-Bis(4-fluorophenvl)-9H-xanthen-9-one (**4g**). Starting with 2 (74 mg, 0.15 mmol), Pd(PPh₃)₂Cl₂ (10 mg, 10 mol %), 4fluorophenylboronic acid (50 mg, 0.36 mmol), KF (58 mg, 1 mmol), and toluene (2 ml), 4g was isolated as a white solid (42 mg, 73%), mp: 173–175 °C. Reaction temperature: 120 °C for 5 h. ¹H NMR (300 MHz, CDCl₃): δ =7.02–7.15 (m, 4H, ArH), 7.24–7.31 (m, 4H, ArH), 7.41 (dd, 1H,=J 0.6, 8.4 Hz, ArH), 7.58-7.65 (m, 4H, ArH), 8.11 (dd, 1H, J=1.6, 8.0 Hz, ArH). ¹⁹F NMR (282.4 MHz, CDCl₃): $\delta = -115.3$, -112.7. ¹³C NMR (75.5 MHz, CDCl₃): $\delta = 114.6$ (d, *I*_{FC}=21.5 Hz, CH), 115.6 (CH), 116.2 (d, *J*_{EC}=21.5 Hz, CH), 117.5 (CH), 118.0, 122.0 (C), 124.0, 126.1, 126.9 (CH), 129.1 (d, J_{EC}=8.3 Hz, CH), 130.1 (d, J_{EC}=7.7 Hz, CH), 134.7 (CH), 134.8 (d, J_{EC}=3.3 Hz, C), 137.6 (d, J_{EC}=3.9 Hz, C), 143.8, 145.2, 155.5, 157.7 (C), 162.0 (d, J_{F,C}=245.8 Hz, CF), 163.4 (d, J_{F,C}=249.3 Hz, CF), 176.7 (CO). IR (KBr): v=3060, 2921, 2852 (w), 1658 (s), 1619 (w), 1602, 1594 (s), 1551 (w), 1513, 1506, 1465 (s), 1426 (m), 1404 (w), 1380, 1357 (m), 1338 (w), 1313 (m), 1303 (w), 1222 (s), 1173 (w), 1156, 1145 (m), 1118, 1103, 1065, 1020, 1013, 960 (w), 945, 926 (m), 894, 867, 851 (w), 825 (s), 811, 779 (w), 753 (s), 733, 719, 697, 676, 668, 644, 637, 618, 604, 586, 569 (w), 549 (m) cm⁻¹. GC-MS (EI, 70 eV): m/z (%)=384 ([M]⁺, 46), 383 ([M-H]⁺, 100), 367 (04), 325 (04). HRMS (EI, 70 eV): calcd for C₂₅H₁₃F₂O₂ [M–H]⁺: 383.08781; found: 383.08785.

2.3. General procedure B for Suzuki–Miyaura cross-coupling reactions to synthesize 5a–i

A 1,4-dioxane solution of of 9-oxo-9*H*-xanthene-1,3-diyl bis(-trifluoromethanesulfonate) **2** (0.15 mmol), Pd(PPh₃)₄ (3 mol %), arylboronic acid (1.1 equiv), and K₃PO₄ (1.5 equiv) was heated at 80 °C for 7 h under argon atmosphere. After cooling to 20 °C, CH₂Cl₂ (30 ml) was added and filtered then the filtrate was concentrated in vacuo. The residue was purified by column chromatography (EtOAc/heptanes).

2.3.1. 4-(3-(4-Methoxyphenyl)-9-oxo-9H-xanthen-1-yl)phenyl trifluoromethanesulfonate (5a). Starting with 2 (74 mg, 0.15 mmol), Pd(PPh₃)₄ (5 mg, 3 mol %), 4-methoxyphenylboronic acid (24 mg, 0.17 mmol), K₃PO₄ (48 mg, 0.23 mmol), and dioxane (2 ml), **5a** was isolated as a white solid (61 mg, 90%), mp: 191-193 °C. Reaction temperature: 80 °C for 7 h. ¹H NMR (300 MHz, CDCl₃): δ =3.79 (s, 3H, OCH₃), 6.95 (d, 2H, *J*=8.7 Hz, ArH), 7.26-7.39 (m, 3H, ArH), 7.50 (d, 2H, J=8.8 Hz, ArH), 7.59 (d, 1H, J=1.5 Hz, ArH), 7.62-7.67 (m, 1H, ArH), 8.27 (dd, 1H, J=1.4, 7.9 Hz, ArH). ¹⁹F NMR (282.4 MHz, CDCl₃): $\delta = -73.3$. ¹³C NMR (62.9 MHz, CDCl₃): $\delta = 55.4$ (OCH₃), 113.5 (C), 114.8, 115.5, 115.9, 117.5 (CH), 118.9 (q, I_{CF}=320.3 Hz, CF₃), 122.1 (C), 124.6, 126.9, 128.4 (CH), 129.4 (C), 135.3 (CH), 147.3, 147.9, 155.3, 157.3, 161.1 (C), 174.7 (CO). IR (KBr): v=3072, 3012, 2971, 2941, 2912, 2842 (w), 1658, 1628, 1609 (s), 1545 (w), 1519 (s), 1473 (w), 1461, 1406, 1360 (m), 1335 (w), 1315, 1300 (m), 1282, 1270 (w), 1240, 1224 (m), 1204 (s), 1179, 1166, 1150 (w), 1137 (s), 1113, 1086, 1066 (w), 1031, 1012 (s), 966 (w), 939 (m), 877, 871, 851 (w), 833, 814, 806, 782, 767, 759 (m), 741, 724, 691, 680, 667, 642 (w), 610 (m), 595 (s), 574, 550, 542 (w) cm⁻¹. GC-MS (EI, 70 eV): m/z (%)=450 ([M]⁺, 100), 317 (23), 302 (13), 289 (34), 258 (16), 246 (12), HRMS (EI, 70 eV): calcd for $C_{21}H_{13}F_3O_6S_1 [M]^+$: 450.03794; found: 450.03830.

2.3.2. 4-(3-(2-Methoxyphenyl)-9-oxo-9H-xanthen-1-yl)phenyl trifluoromethanesulfonate (**5b**). Starting with **2** (74 mg, 0.15 mmol), Pd(PPh₃)₄ (5 mg, 3 mol %), 2-methoxyphenylboronic acid (24 mg, 0.17 mmol), K₃PO₄ (48 mg, 0.23 mmol), and dioxane (2 ml), **5b** was isolated as a white solid (52 mg, 77%), mp: 145-147 °C. Reaction temperature: 80 °C for 7 h. ¹H NMR (300 MHz, CDCl₃): δ =3.79 (s, 3H, OCH₃), 6.89-7.04 (m, 2H, ArH), 7.29-7.40 (m, 5H, ArH), 7.57–7.68 (m, 2H, ArH), 8.29 (dd, 1H, J=1.4, 7.9 Hz, ArH). ¹⁹F NMR (282.4 MHz, CDCl₃): $\delta = -73.4$. ¹³C NMR (62.9 MHz, CDCl₃): $\delta = 55.5$ (OCH₃), 111.6 (CH), 113.8 (C), 117.6 (CH), 118.9 (q, J_{CF}=320.8 Hz, CF₃), 119.1, 119.4, 121.3 (CH), 122.1 (C), 124.5 (CH), 126.6 (C), 126.9, 130.5, 131.0, 135.2 (CH), 145.6, 146.9, 155.4, 156.5, 156.9 (C), 175.0 (CO), IR (KBr): v=3067, 3005, 2950, 2918, 2842 (w), 1659, 1627, 1609 (s), 1581, 1547, 1504 (w), 1471, 1463 (m), 1441 (w), 1422, 1406 (s), 1357 (m), 1334 (w), 1315 (m), 1286, 1271 (w), 1247, 1240 (m), 1225 (w), 1203 (s), 1163 (w), 1140 (s), 1125, 1111 (m), 1064, 1052 (w), 1035 (m), 1015 (s), 958 (w), 890 (s), 870 (m), 852 (w), 814 (s), 800 (w), 784 (m), 757, 750 (s), 721, 701, 682, 661, 634, 626, 606 (w), 592, 575 (s), 544 (w) cm⁻¹. GC-MS (EI, 70 eV): m/z (%)=450 ([M]⁺, 100), 317 (20), 302 (11), 299 (12), 289 (35), 271 (10), 258 (11). HRMS (EI, 70 eV): calcd for C₂₁H₁₃F₃O₆S₁ [M]⁺: 450.03794; found: 450.03826.

2.3.3. 4-(3-(3,5-Dimethylphenyl)-9-oxo-9H-xanthen-1-yl)phenyl trifluoromethanesulfonate (5c). Starting with 2 (74 mg, 0.15 mmol), Pd(PPh₃)₄ (5 mg, 3 mol %), 3,5-dimethylphenylboronic acid (24 mg, 0.17 mmol), K₃PO₄ (48 mg, 0.23 mmol), and dioxane (2 ml), 5c was isolated as a white solid (48 mg, 72%), mp: 210 °C. Reaction temperature: 80 °C for 7 h. ¹H NMR (300 MHz, CDCl₃): δ =2.35 (s, 6H, 2CH₃), 7.06 (s, 1H, ArH), 7.17 (br s, 2H, ArH), 7.29-7.37 (m, 2H, ArH), 7.42 (dd, 1H, J=0.6, 8.4 Hz, ArH), 7.65-7.71 (m, 2H, ArH), 8.30 (dd, 1H, I=1.5, 8.0 Hz, ArH). ¹⁹F NMR (282.4 MHz, CDCl₃): $\delta = -73.3$.¹³C NMR (75.5 MHz, CDCl₃): δ=21.4 (2CH₃), 114.0 (C), 116.5, 116.6, 117.6 (CH), 118.9 (q, J_{CF}=320.7 Hz, CF₃), 122.2 (C), 124.7, 125.0, 127.0, 131.4, 135.3 (CH), 137.3, 139.1, 147.8, 148.2, 155.4, 157.9 (C), 174.7 (CO). IR (KBr): v=3097, 3067, 3012, 2953, 2920, 2851, 2732, 2664 (w), 1661, 1626, 1610 (s), 1548, 1492 (w), 1464 (m), 1427 (s), 1407 (w), 1395 (m), 1375 (w), 1359 (m), 1310 (w), 1214, 1204, 1187 (s), 1160 (w), 1137 (s), 1110 (m), 1081 (w), 1038, 1016 (m), 957 (w), 914 (m), 901 (w), 843, 834 (s), 798 (w), 716, 749 (s), 722, 689 (w), 666 (m), 656, 631, 609 (w), 594, 572 (s), 547 (w) cm⁻¹. GC–MS (EI, 70 eV): m/z(%)=448 ([M]⁺, 100), 384 (40), 356 (20), 316 (65), 300 (17), 287 (44), 281 (13), 272 (11), 259 (16). HRMS (EI, 70 eV): calcd for C₂₂H₁₅F₃O₅S₁ [M]⁺: 448.05868; found: 448.05883.

2.3.4. 4-(3-(3-Chlorophenyl)-9-oxo-9H-xanthen-1-yl)phenyltrifluoromethanesulfonate (5d). Starting with 2 (74 mg, 0.15 mmol), Pd(PPh₃)₄ (5 mg, 3 mol %), 3-chlorophenylboronic acid (25 mg, 0.17 mmol), K₃PO₄ (48 mg, 0.23 mmol), and dioxane (2 ml), 5d was isolated as a white solid (55 mg, 80%), mp: 172 °C. Reaction temperature: 80 °C for 7 h. ¹H NMR (300 MHz, CDCl₃): δ =7.24 (d, 1H, J=0.8 Hz, ArH), 7.28-7.34 (m, 1H, ArH), 7.36-7.44 (m, 4H, ArH), 7.50–7.51 (m, 1H, ArH), 7.61–7.69 (m, 2H, ArH), 8.25 (dd, 1H, *J*=1.6, 8.0 Hz, ArH). ¹⁹F NMR (282.4 MHz, CDCl₃): δ =-73.3. ¹³C NMR (62.9 MHz, CDCl₃): δ=114.4 (C), 116.3, 116.7, 117.6 (CH), 118.9 (q, *I*_{CF}=321.1 Hz, CF₃), 122.1 (C), 124.8, 125.4, 126.9, 127.3, 129.7, 130.7 (CH), 135.4 (C), 135.5 (CH), 139.0, 146.1, 147.9, 155.2, 157.3 (C), 175.0 (CO). IR (KBr): v=3077, 2923, 2851, 2789, 2667 (w), 1665, 1627, 1607 (s), 1572, 1549, 1513 (w), 1502, 1470, 1460 (m), 1407 (w), 1392, 1357 (m), 1335 (w), 1310 (m), 1283, 1245 (w), 1222, 1192 (s), 1166 (m), 1136 (s), 1112, 1105, 1082 (w), 1032, 1012 (s), 995, 960 (w), 947 (m), 902 (s), 881, 862 (w), 823 (s), 800 (w), 785, 759, 721 (m), 694 (w), 678, 662 (m), 637, 631, 606 (w), 590, 572 (s), 548 (w) cm⁻¹. GC–MS (EI, 70 eV): m/z (%)=456 ([M, ${}^{37}Cl]^+$, 41), 454 ([M, ${}^{35}Cl]^+$, 100), 392 (21), 390 (62), 364 (11), 362 (29), 295 (11), 293 (39), 286 (28), 267 (16), 265 (43), 258 (26). HRMS (ESI-TOF/MS): calcd for C₂₀H₁₁ClF₃O₅S₁ [M+H, ³⁵Cl]⁺: 454.99623; found: 454.99651, calcd for C₂₀H₁₁ClF₃O₅S [M+H, ³⁷Cl]⁺: 456.99351; found: 456.99363.

2.3.5. 4-(3-(4-Chlorophenyl)-9-oxo-9H-xanthen-1-yl)phenyl trifluoromethanesulfonate (**5e**). Starting with **2** (74 mg, 0.15 mmol), Pd(PPh₃)₄ (5 mg, 3 mol %), 4-chlorophenylboronic acid (25 mg, 0.17 mmol), K₃PO₄ (48 mg, 0.23 mmol), and dioxane (2 ml), 5e was isolated as a white solid (58 mg, 85%), mp: 200-202 °C. Reaction temperature: 80 °C for 7 h. ¹H NMR (300 MHz, CDCl₃): δ =7.27 (d, 1H, *I*=0.8 Hz, ArH), 7.32–7.37 (m, 1H, ArH), 7.39–7.52 (m, 5H, ArH), 7.64–7.71 (m, 2H, ArH), 8.29 (dd, 1H, *J*=1.5, 7.9 Hz, ArH). ¹⁹F NMR $(282.4 \text{ MHz}, \text{CDCl}_3)$: $\delta = -73.3$. ¹³C NMR (62.9 MHz, CDCl₃): $\delta = 114.3$ (C), 116.4, 116.5, 117.6 (CH), 118.9 (q, J_{CF}=320.8 Hz, CF₃), 122.1 (C), 124.5, 127.0, 128.5, 129.7, 135.5 (CH), 135.7, 136.2, 146.4, 148.0, 153.3, 157.4 (C), 175.0 (CO). IR (KBr): v=3110, 3076, 3038 (w), 1666, 1628, 1608 (s), 1591, 1547, 1505 (w), 1461 (m), 1426 (s), 1391, 1357, 1312 (m), 1285, 1267 (w), 1246 (m), 1221, 1194 (s), 1165 (w), 1091, 1031, 1010 (m), 965 (w), 937 (m), 887 (s), 866 (w), 830, 813, 798 (m), 760 (s), 723 (m), 689, 678 (w), 664 (m), 635, 620 (w), 607 (m), 590, 573 (s), 532 (w) cm⁻¹. GC–MS (EI, 70 eV): m/z (%)=456 ([M, ³⁷Cl]⁺, 46), 454 ([M, ³⁵Cl]⁺, 100), 392 (18), 390 (61), 364 (09), 362 (30), 322 (20), 295 (13), 293 (35), 286 (23), 267 (12), 265 (33), 258 (38). HRMS (EI, 70 eV): calcd for $C_{20}H_{10}ClF_{3}O_5S_1$ [M, ³⁵Cl]⁺: 453.98841; found: 453.98857, calcd for $C_{20}H_{10}ClF_{3}O_5S_1$ [M, ³⁷Cl]⁺: 455.98546; found: 455.98437.

2.3.6. 4-(3-(4-Fluorophenyl)-9-oxo-9H-xanthen-1-yl)phenyl trifluoromethanesulfonate (5f). Starting with 2 (74 mg, 0.15 mmol), Pd(PPh₃)₄ (5 mg, 3 mol %), 4-flourophenylboronic acid (23 mg, 0.17 mmol), K₃PO₄ (48 mg, 0.23 mmol), and dioxane (2 ml), 5f was isolated as a white solid (50 mg, 76%), mp: 187 °C. Reaction temperature: 80 °C for 7 h. ¹H NMR (300 MHz, CDCl₃): δ =7.14 (t, 2H, *J*=8.6 Hz, ArH), 7.26 (d, 1H, *J*=0.8 Hz, ArH), 7.31–7.36 (m, 1H, ArH), 7.40 (br d, 1H, J=8.4 Hz, ArH), 7.52-7.58 (m, 2H, ArH), 7.62 (d, 1H, *I*=1.7 Hz, ArH), 7.67 (ddd, 1H, *I*=1.7, 7.0, 8.5 Hz, ArH), 8.28 (dd, 1H, I=1.6, 7.9 Hz, ArH). ¹⁹F NMR (282.4 MHz, CDCl₃): $\delta = -111.1$, -73.3. ^{13}C NMR (75.5 MHz, CDCl_3): $\delta{=}114.4$ (C), 116.4 (2CH), 116.6 (d, J_{F,C}=21.7 Hz, CH), 117.6 (CH), 118.9 (q, J_{C,F}=321.2 Hz, CF₃), 122.1 (C), 124.8, 127.0 (CH), 129.1 (d, J_{EC}=8.6 Hz, CH), 133.5 (d, J_{EC}=3.4 Hz, C), 135.5 (CH), 145.6, 148.0, 155.3, 157.3 (C), 163.8 (d, J_{EC}=250.9 Hz, CF), 175.0 (CO). IR (KBr): v=2922, 2852 (w), 1661, 1626, 1608 (s), 1550 (w), 1512, 1463 (m), 1435 (w), 1423 (s), 1404 (w), 1394, 1361 (m), 1334 (w), 1309 (m), 1286 (w), 1241, 1226 (m), 1216, 1197 (s), 1161, 1151 (w), 1134 (s), 1112, 1061 (w), 1037 (s), 938 (m), 872 (w), 823 (s), 819 (w), 797 (m), 770 (s), 760, 725, 700, 666, 659, 638 (w), 611, 594 (s), 571, 543 (w) cm⁻¹. GC-MS (EI, 70 eV): m/z (%)=438 ([M]⁺, 100), 374 (52), 346 (29), 305 (20), 277 (56), 249 (43), 220 (38). HRMS (EI, 70 eV): calcd for C₂₀H₁₀F₄O₅S₁ [M]⁺: 438.01796; found: 438.01796.

2.3.7. 4-(3-(4-(tert-Butyl)phenyl)-9-oxo-9H-xanthen-1-yl)phenyltrifluoromethanesulfonate (5g). Starting with 2 (74 mg, 0.15 mmol), Pd(PPh₃)₄ (5 mg, 3 mol %), 4-tert-butylphenylboronic acid (29 mg, 0.17 mmol), K₃PO₄ (48 mg, 0.23 mmol), and dioxane (2 ml), 5g was isolated as a white solid (64 mg, 91%), mp: 150-152 °C. Reaction temperature: 80 °C for 7 h. ¹H NMR (300 MHz, CDCl₃): δ =1.31 (s, 9H, 3CH₃), 7.29–7.35 (m, 2H, ArH), 7.39 (br d, 1H, J=8.4 Hz, ArH), 7.46-7.54 (m, 4H, ArH), 7.64-7.70 (m, 2H, ArH), 8.28 (dd, 1H, J=1.5, 7.9 Hz, ArH). $^{19}\mathrm{F}$ NMR (282.4 MHz, CDCl_3): $\delta{=}{-}73.3.$ $^{13}\mathrm{C}$ NMR (62.9 MHz, CDCl₃): δ=31.2 (3CH₃), 34.1, 113.7 (C), 116.1, 116.4, 117.6 (CH), 118.9 (q, J_{CF}=320.2 Hz, CF₃), 122.1 (C), 124.7, 126.4, 126.9, 127.0 (CH), 134.3 (C), 135.3 (CH), 147.7, 147.9, 153.2, 155.3, 157.3 (C), 174.8 (CO). IR (KBr): v=3075, 3040, 2965, 2924, 2868 (w), 1658, 1624, 1607 (s), 1545, 1524, 1494 (w), 1462, 1422 (s), 1397, 1359 (m), 1334, 1309, 1285, 1268, 1242, 1230 (w), 1209, 1186 (s), 1166 (m), 1137 (s), 1111 (m), 1080 (w), 1035, 1014 (s), 967 (w), 939, 895 (m), 881, 868, 853, 841 (w), 827, 813, 802, 770 (s), 724, 727, 721, 692 (w), 664 (m), 641, 622, 608 (w), 594 (s), 569, 545 (m) cm⁻¹. GC–MS (EI, 70 eV): *m/z* (%)=476 ([M]⁺, 32), 461 (100), 328 (04), 300 (18), 254 (04). HRMS (ESI-TOF/ MS): calcd for $C_{24}H_{20}F_{3}O_{5}S_{1}$ [M+H]⁺: 477.09781; found: 477.09730.

2.3.8. 4-(3-(4-Acetylphenyl)-9-oxo-9H-xanthen-1-yl)phenyl trifluoromethanesulfonate (**5h**). Starting with **2** (74 mg, 0.15 mmol),

Pd(PPh₃)₄ (5 mg, 3 mol %), 4-acetylphenylboronic acid (27 mg, 0.17 mmol), K₃PO₄ (48 mg, 0.23 mmol), and dioxane (2 ml), **5h** was isolated as a white solid (58 mg, 83%), mp: 203 °C. Reaction temperature: 80 °C for 7 h. ¹H NMR (300 MHz, CDCl₃): δ =2.58 (s, 3H, COCH₃), 7.31–7.40 (m, 3H, ArH), 7.63–7.69 (m, 4H, ArH), 8.0 (d, 2H, *I*=8.2 Hz, ArH), 8.3 (d, 1H, *I*=7.1 Hz, ArH). ¹⁹F NMR (282.4 MHz, CDCl₃): $\delta = -73.3$. ¹³C NMR (62.9 MHz, CDCl₃): $\delta = 26.7$ (CH₃), 114.6 (C), 116.5, 117.0, 117.6 (CH), 118.9 (q, J_{C,F}=321.1 Hz, CF₃), 122.1 (C), 124.9, 127.0, 127.5, 129.3, 135.6 (CH), 137.7, 141.4, 146.2, 148.0, 155.2, 157.3 (C), 174.7, 197.2 (CO). IR (KBr): v=3105, 3076, 3005, 2919, 2850 (w), 1668, 1659, 1628, 1606 (s), 1545, 1519 (w), 1478, 1470 (m), 1422 (s), 1394, 1358 (m), 1337 (w), 1314 (m), 1287 (w), 1267, 1261, 1243 (m), 1208, 1199 (s), 1166, 1155 (w), 1134 (s), 1112, 1075, 1058 (w), 1034, 1012 (s), 961 (w), 938 (m), 887 (s), 863 (w), 834, 816, 802, 758 (s), 742, 720 (w), 665 (m), 623 (w), 609 (m), 595, 586, 573 (s), 550 (w) cm⁻¹. GC–MS (EI, 70 eV): m/z (%)=462 ([M]⁺, 76), 447 (96), 383 (31), 355 (26), 341 (11), 287 (21), 258 (28), 254 (14), 44 (100). HRMS (EI, 70 eV): calcd for $C_{22}H_{13}F_3O_6S_1$ [M]⁺: 462.03794; found: 462.03783.

2.3.9. 4-(9-Oxo-3-(4-(trifluoromethyl)phenyl)-9H-xanthen-1-yl) phenyl trifluoromethanesulfonate (5i). Starting with 2 (74 mg, 0.15 mmol), Pd(PPh₃)₄ (5 mg, 3 mol -%), 4-(triflouromethyl)phenylboronic acid (31 mg, 0.17 mmol), K₃PO₄ (48 mg, 0.23 mmol), and dioxane (2 ml), **5h** was isolated as a white solid (63 mg, 86%), mp: 185–187 °C. Reaction temperature: 80 °C for 7 h. ¹H NMR (300 MHz, CDCl₃): δ=7.30-7.42 (m, 3H, ArH), 7.66-7.74 (m, 6H, ArH), 8.28 (dd, 1H, *J*=1.4, 7.9 Hz, ArH). ¹⁹F NMR (282.4 MHz, CDCl₃): $\delta = -73.3$, -62.8. ¹³C NMR (62.9 MHz, CDCl₃): $\delta = 114.7$ (C), 116.6, 117.1, 117.6 (CH), 118.8 (q, J_{CF}=320.9 Hz, CF₃), 122.1 (C), 123.8 (q, J_{CF}=272.4 Hz, CF₃), 124.9 (CH), 126.4 (q, J_{CF}=3.7 Hz, CH), 127.0, 127.7 (CH), 131.6 (q, J_{CF}=32.3 Hz, C-CF₃), 135.6 (CH), 140.8, 146.1, 148.1, 155.3, 157.3 (C), 174.6 (CO). IR (KBr): v=1660 (s), 1631, 1610 (m), 1548, 1524, 1474, 1463 (w), 1424 (s), 1399, 1360 (w), 1322, 1313 (s), 1243 (w), 1219, 1210 (s), 1177, 1156 (w), 1137, 1125, 1110, 1072 (s), 937, 899 (w), 889 (m), 877 (w), 844 (s), 814, 802 (m), 766, 761 (s), 736, 725, 703, 683, 672, 655, 624 (w), 596 (s), 550, 534 (w) cm⁻¹. GC–MS (EI, 70 eV): *m*/*z* (%)=488 ([M]⁺, 100), 469 (10), 424 (83), 396 (37), 355 (12), 327 (42), 299 (66), 258 (18). HRMS (EI, 70 eV): calcd for C₂₁H₁₀F₆O₅S₁ [M]⁺: 488.01476; found: 488.01455.

2.4. General procedure C for the one-pot synthesis of 1,3diarylxanthones 6a—e

A toluene solution9-oxo-9*H*-xanthene-1,3-diyl bis(trifluoromethanesulfonate) **2** (0.2 mmol), Pd(PPh₃)₂Cl₂ (3 mol %), Ar¹B(OH)₂ (1.0 equiv), and KF (3.3 equiv) was heated at 85 °C for 16 h under argon atmosphere. After cooling to 20 °C, Ar²B(OH)₂ (1.4 equiv), Pd(PPh₃)₂Cl₂ (6 mol %), and KF (3.3 equiv), were added reaction mixture was heated at 120 °C for further 7 h. Reaction mixture was cooled again to 20 °C, H₂O was added and the reaction mixture was extracted with CH₂Cl₂ (3×25 ml), organic layers were dried (Na₂SO₄), filtered and then concentrated in vacuo. The residue was purified by column chromatography (EtOAc/heptanes).

2.4.1. 1-(4-Chlorophenyl)-3-(4-ethylphenyl)-9H-xanthen-9-one (**6a**). Starting with **2** (100 mg, 0.20 mmol), Pd(PPh₃)₂Cl₂ (4 mg, 3 mol %) 4-ethylphenylboronic acid (30 mg, 0.20 mmol), KF (38 mg, 0.66 mmol), toluene (3 ml), and Pd(PPh₃)₂Cl₂ (8 mg, 6 mol %), 4-chlorophenylboronic acid (44 mg, 0.28 mmol), KF (38 mg, 0.66 mmol), **6a** was prepared according to the general procedure C, as a white solid (57 mg, 70%), mp: 195–197 °C. Reaction temperature was 85 °C for 16 h and 120 °C for 7 h. ¹H NMR (300 MHz, CDCl₃): δ =1.20 (t, 3H, *J*=7.7 Hz, CH₃), 2.63 (q, 2H, *J*=7.6 Hz, CH₂), 7.20–7.25 (m, 5H, ArH), 7.28 (d, 1H, *J*=1.8 Hz, ArH), 7.32 (d, 2H, *J*=8.4 Hz, ArH), 7.38 (br d, 1H, *J*=8.3 Hz, ArH), 7.54 (d, 2H, *J*=8.2 Hz,

ArH), 7.58–7.65 (m, 2H, ArH), 8.10 (dd, 1H, J=1.5, 7.9 Hz, ArH). ¹³C NMR (75.5 MHz, CDCl₃): $\delta=14.4$ (CH₃), 27.8 (CH₂), 114.4, 116.4 (CH), 116.7, 121.7 (C), 122.9, 124.8, 125.8, 126.2, 126.6, 127.3, 128.9 (CH), 132.2 (C), 133.5 (CH), 134.8, 139.3, 142.2, 144.4, 145.3, 154.5, 156.6 (C), 175.6 (CO). IR (KBr): v=3063, 3031, 2960, 2927, 2869, 1956, 1925, 1866 (w), 1660 (s), 1614 (m), 1600 (s), 1574, 1553, 1519, 1488 (w), 1467, 1460 (m), 1426 (w), 1386, 1355, 1311 (m), 1295, 1262 (w), 1230 (m), 1194, 1172, 1146, 1124, 1100 (w), 1014 (m), 996, 965 (w), 944, 929 (m), 874, 861, 852, 835 (w), 825, 816, 764 (s), 730, 705, 697 (w), 671 (m), 640, 623, 603, 590 (w), 552 (m) cm⁻¹. GC–MS (EI, 70 eV): m/z (%)=412 ([M, ³⁷Cl]⁺, 18), 410 ([M, ³⁵Cl]⁺, 53), 409 ([M–H, ³⁵Cl]⁺, 100), 394 (20), 373 (08). HRMS (ESI-TOF/MS): calcd for C₂₇H₂₀ClO₂ [M+H, ³⁷Cl]⁺: 413.11288; found 411.11476, calcd For C₂₇H₂₀ClO₂ [M+H, ³⁷Cl]⁺: 413.11288; found 413.11290.

2.4.2. 3-(4-(tert-Butyl)phenyl)-1-(4-methoxyphenyl)-9H-xanthen-9one (**6b**). Starting with **2** (100 mg, 0.20 mmol), Pd(PPh₃)₂Cl₂ (4 mg, 3 mol %) 4-tert-butylphenylboronic acid (36 mg, 0.20 mmol), KF (38 mg, 0.66 mmol), toluene (3 ml), and Pd(PPh₃)₂Cl₂ (8 mg, 6 mol %), 4-methoxyphenylboronic acid (43 mg, 0.28 mmol), KF (38 mg, 0.66 mmol), 6b was prepared according to the general procedure C, as a white solid (68 mg, 78%), mp: 225-227 °C. Reaction temperature was 85 °C for 16 h and 120 °C for 7 h. ¹H NMR (300 MHz, CDCl₃): δ=1.30 (s, 9H, 3CH₃), 3.79 (s, 3H, OCH₃), 6.91 (d, 2H, J=8.8 Hz, ArH), 7.21-7.27 (m, 3H, ArH), 7.33 (d, 1H, J=1.8 Hz, ArH), 7.36–7.44 (m, 3H, ArH), 7.55–7.59 (m, 3H, ArH), 7.61 (d, 1H, *J*=1.8 Hz, ArH), 8.12 (dd, 1H, *J*=1.5, 7.9 Hz, ArH). ¹³C NMR (62.9 MHz. CDCl₃): δ =31.3 (3CH₃), 34.7 (C), 55.2 (OCH₃), 113.1, 114.9, 117.3 (CH), 117.9, 122.9 (C), 123.8, 126.1, 126.3, 126.9, 127.1, 129.8 (CH), 134.2 (C), 134.3 (CH), 135.9, 144.4, 145.9, 152.1, 155.1, 157.5, 158.9 (C), 176.8 (CO). IR (KBr): v=3034, 2953, 2910, 2866, 2838 (w), 1650 (s), 1612 (m), 1599 (s), 1549 (w), 1467 (s), 1422, 1386 (w), 1311, 1282 (m), 1245 (s), 1173 (m), 1151, 1124, 1104 (w), 1024, 948, 927 (m), 915, 882, 868, 854, 848 (w), 821, 769 (s), 761, 723 (m), 689 (w), 676 (m), 646, 624, 606, 581, 557, 546, 528 (w) cm⁻¹. GC–MS (EI, 70 eV): *m*/*z* (%)=434 ([M]⁺, 85), 433 ([M–H]⁺, 100), 419 (17), 417 (08), 390 (07). HRMS (EI, 70 eV): calcd for $C_{30}H_{25}O_3$ [M–H]⁺: 433.17982; found: 433.17978; calcd for C₃₀H₂₆O₃ [M]⁺: 434.18765; found: 434.18620.

2.4.3. 1-(4-Methoxyphenyl)-3-(4-(trifluoromethyl)phenyl)-9Hxanthen-9-one (6e). Starting with 2 (100 mg, 0.20 mmol), Pd(PPh₃)₂Cl₂ (4 mg, 3 mol %) 4-(trifluoromethyl)phenylboronic acid (38 mg, 0.20 mmol), KF (38 mg, 0.66 mmol), toluene (3 ml), and Pd(PPh₃)₂Cl₂ (8 mg, 6 mol %), 4-methoxylphenylboronic acid (43 mg, 0.28 mmol), KF (38 mg, 0.66 mmol), 6d was prepared according to the general procedure C, as a yellow solid (76 mg, 85%), mp: 195-197 °C. Reaction temperature was 85 °C for 16 h and 120 °C for 7 h. ¹H NMR (300 MHz, CDCl₃): δ =3.81 (s, 3H, OCH₃), 6.91 (d, 2H, *J*=8.6 Hz, ArH), 7.23–7.28 (m, 3H, ArH), 7.33 (d, 1H, *J*=1.9 Hz, ArH), 7.41 (br d, 1H, J=8.1 Hz, ArH), 7.60-7.75 (m, 6H, ArH), 8.13 (dd, 1H, J=1.5, 8.1 Hz, ArH). ¹⁹F NMR (282.4 MHz, CDCl₃): δ =-62.6. ¹³C NMR (75.5 MHz, CDCl₃): δ=54.2 (OCH₃), 112.2, 114.6, 116.4 (CH), 117.7, 121.8 (C), 122.9 (CH), 123.0 (q, J_{C,F}=272.4 Hz, CF₃), 125.1 (q, J_{CF}=3.9 Hz, CH), 125.3, 125.9, 126.7, 128.7 (CH), 129.7 (q, J_{CF}=32.5 Hz, C–CF₃), 132.7 (C), 133.6 (CH), 141.4, 143.4, 143.9, 154.4, 156.7, 158.0 (C), 175.7 (CO). IR (KBr): v=3078, 3052, 3031, 2966, 2920, 2828, 2087, 1946, 1923 (w), 1652 (s), 1613 (m), 1599 (s), 1575, 1548 (m), 1513, 1468 (s), 1454, 1446 (m), 1321, 1309 (s), 1292 (m),

1261, 1251 (s), 1230, 1206, 1176 (w), 1160 (m), 1146 (w), 1107, 1070, 1026, 1013 (s), 970, 956, 926, 888, 853 (w), 836, 830 (s), 801 (m), 758 (s), 736, 728, 704, 681, 670, 565, 624, 611, 601, 589, 578, 556, 530 (w) cm⁻¹. GC–MS (EI, 70 eV): m/z (%)=446 ([M]⁺, 58), 445 ([M–H]⁺, 100), 402 (20). HRMS (EI, 70 eV): calcd for C₂₇H₁₆F₃O₃ [M–H]⁺: 445.10461; found: 445.10501, calcd for. C₂₇H₁₇F₃O₃ [M]⁺: 446.11243; found: 446.11099.

References and notes

- Xiao, H.; Yang, L.; Zenai, C.; Guangming, L.; Jinfu, Q. J. Chin. Pharm. Sci. 2001, 10, 172–174.
- 2. Ee, G. C. L.; Lim, C. K.; Lee, H. L. J. Asian Nat. Prod. Res. 2006, 8, 567-570.
- Wen, L.; Lin, Y.-C.; She, Z.-G.; Du, D.-S.; Chan, W.-L.; Zheng, Z. H. J. Asian Nat. Prod. Res. 2008, 10, 133–137.
- (a) Mahabusarakam, W.; Nuangnaowarat, W.; Taylor, W. C. *Phytochemistry* 2006, *67*, 470–474; (b) Gnerre, C.; Thull, U.; Gailland, P.; Carrupt, P. A.; Testa, B.; Fernandes, E.; Silva, F.; Pinto, M.; Pinto, M. M. M.; Wolfender, J.-L.; Hostettmann, K.; Cruciani, G. *Helv. Chim. Acta* 2001, *84*, 552–570.
- 5. Lesch, B.; Braese, S. Angew. Chem., Int. Ed. 2004, 43, 115-118.
- (a) Garrity, A. R.; Morton, G. A. R.; Morton, J. C. U.S. Patent 6,730,333, 2004. (b) Sellés, A. J. N.; Castro, H. T. V.; Agüero, J.; González, J.; Naddeo, F.; De Simone, F.; Rastrelli, L. J. Agric. Food Chem. 2002, 50, 762–766.
- (a) Dube, M.; Zunker, K.; Neidhart, S.; Carle, R.; Steinhart, H.; Paschke, A. J. Agric. Food Chem. 2004, 52, 3938–3945; (b) Pfister, J. R.; Ferraresi, R. W.; Harrison, I. T.; Rooks, W. H.; Freid, J. H. J. Med. Chem. 1978, 21, 669–672.
- Rukachaisirikul, V.; Kamkaew, M.; Sukavisit, D.; Taylor, W. C. J. Nat. Prod. 2003, 66, 1531–1535.
- (a) Abdel-Lateff, A.; Klemke, C.; König, G. M.; Wright, A. D. J. Nat. Prod. 2003, 66, 706–708; (b) Fukai, T.; Yonekawa, M.; Hou, A.-J.; Nomura, T.; Sun, H.-D.; Uno, J. J. Nat. Prod. 2003, 66, 1118–1120; (c) Mackeen, M. M.; Ali, A. M.; Lajis, N. H.; Kawazu, K.; Hassan, Z.; Amran, M.; Habsah, M.; Mooi, L. Y.; Mohamed, S. M. J. Ethnopharmacol. 2000, 72, 395–402.
- (a) Park, H. H.; Park, Y.-D.; Han, J.-M.; Im, K.-R.; Lee, B. W.; Jeong, I. Y.; Jeong, T.-S.; Lee, W. S. *Bioorg. Med. Chem. Lett.* **2006**, *16*, 5580–5583; (b) Lin, C. N.; Chung, M. I.; Liou, S. J.; Lee, T. H.; Wang, J. P. J. Pharm. Pharmacol. **1996**, *48*, 532–538.
- (a) Riscoe, M.; Kelly, J. X.; Winter, R. *Curr. Med. Chem.* **2005**, *12*, 2539–2549; (b) Portela, C.; Alfonso, C. M. M.; Pinto, M. M. M.; Ramos, M. J. *Bioorg. Med. Chem.* **2004**, *12*, 3313–3321; (c) Dua, V. K.; Ojha, V. P.; Roy, R.; Joshi, B. C.; Valecha, N.; Devi, C. U.; Batnagar, M. C.; Sharma, V. P.; Subbarao, S. K. *J. Ethnopharmacol.* **2004**, *95*, 247–251.
- 12. Alj, V.; De bruyne, T.; Pieters, A. S. Planta Med. 1998, 64, 97-109.
- 13. Peres, V.; Nagem, T. J.; De Oliveira, F. F. Phytochemistry 2000, 55, 683-710.
- 14. Ichikib, H.; Okadab, M.; Ishidac, T.; Tanigawaa, K. Phytomedicine 2001, 8, 85-87.
- 15. Palmer, B. D.; Henare, K.; Ching, M. J. Med. Chem. 2007, 50, 3759-3764.
- 16. Casillas, L. K.; Townsend, C. A. J. Org. Chem. 1999, 64, 4050-4059.
- 17. Zhao, J.; Larock, R. C. J. Org. Chem. 2007, 72, 583-588.
- 18. Dang, A.-T.; Dawe, L. N.; Bodwell, G. J. Org. Lett. 2008, 10, 233-236.
- 19. Su, Q.-G.; Liu, Y.; Xi, L.-J. Invest. New Drugs 2011, 29, 1230-1240.
- 20. Zhao, L.; Xie, F.; Cheng, G.; Hu, Y. Angew. Chem., Int. Ed. 2009, 48, 6520-6523.
- 21. Liu, Y.; Huang, L.; Xie, F.; Hu, Y. J. Org. Chem. 2010, 75, 6304-6307.
- Esteves, I. C.; Santos, C. M. M.; Cristela, M. B.; Silva, A. M. S.; Cavaleiro, J. A. S. Synlett 2011, 1403–1406.
- Santos, C. M. M.; Cristela, M. B.; Silva, A. M. S.; Cavaleiro, J. A. S. Synlett 2005, 3095–3098.
- Santos, C. M. M.; Cristela, M. B.; Silva, A. M. S.; Cavaleiro, J. A. S. Synlett 2007, 3113–3116.
- Santos, C. M. M.; Cristela, M. B.; Silva, A. M. S.; Cavaleiro, J. A. S. Eur. J. Org. Chem. 2009, 2642–2660.
- 26. Gardikis, Y.; Tsoungas, P. G.; Cordopatis, P. J. Heterocycl. Chem. 2011, 83, 1077–1091.
- 27. CCDC-878328 contains all crystallographic details of this publication and is available free of charge at www.ccdc.cam.ac.uk/conts/retrieving.html or can be ordered from the following address: Cambridge Crystallographic Data Centre, 12 Union Road, GB-Cambridge CB21EZ; Fax: (+44) 1223-336-033; or deposit@ ccdc.cam.ac.uk.
- 28. Akrawi, O. A.; Hussain, M.; Langer, P. Tetrahedron Lett. 2011, 52, 1093-1095.
- For reviews of cross-coupling reactions of polyhalogenated heterocycles, see:
 (a) Schröter, S.; Stock, C.; Bach, T. *Tetrahedron* 2005, 61, 2245–2254;
 (b) Schnürch, M.; Flasik, R.; Khan, A. F.; Spina, M.; Mihovilovic, M. D.; Stanetty, P. *Eur. J. Org. Chem.* 2006, 3283–3290.
- 30. Handy, S. T.; Zhang, Y. Chem. Commun. 2006, 299-301.